Identifying new predictive biomarkers is vital for the development of targeted therapies for lung cancer, especially therapies for overcoming resistance to drugs such as osimertinib in EGFR-mutated NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.